go back

Ciltacabtagene Autoleucel (Carvykti) CAR-T Therapy

Delaware rates for HCPCS Q2056

Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated October 2026.

How much rates vary

Facilitymedian $588,844 · 10th to 90th $588,844 to $776,247Professionalmedian $588,844 · 10th to 90th $588,844 to $954,993
$1Mfacility $588,844professional $588,844

Distribution of negotiated rates across all payers (price axis is log-scale). Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Aetna
Setting
Facility
Modifier
None
Typical Low
$588,843.66
Median
$588,843.66
Typical High
$588,843.66
Aetna
Setting
Professional
Modifier
None
Typical Low
$588,843.66
Median
$588,843.66
Typical High
$588,843.66
Cigna
Setting
Facility
Modifier
None
Typical Low
$776,247.12
Median
$776,247.12
Typical High
$776,247.12
Cigna
Setting
Professional
Modifier
None
Typical Low
$954,992.59
Median
$954,992.59
Typical High
$954,992.59